Home/Premenstrual Dysphoric Disorder (PMDD)
Condition Deep-Dive

Premenstrual Dysphoric Disorder (PMDD)

A severe, cyclical mood disorder triggered by normal hormonal fluctuations during the luteal phase. Affects an estimated 1.8% to 5.8% of menstruating women in the US each year11. Now classified by DSM-⁠5 as a mental health disorder, but driven by a treatable biology, not "just bad PMS."

Hormonal & Women's Health Evidence-Based

Last updated:

โš ๏ธ Medication safety: please read first. The nutrition and supplement approaches on this page are meant to work alongside your prescribed treatment, never to replace it. Never stop, reduce or change your antidepressant or hormonal medication without your prescriber's guidance. Doing so can be dangerous. Several supplements interact with antidepressant or hormonal medication, so talk to your prescriber or pharmacist before starting anything on this page.
Definition

What Is PMDD?

PMDD is a severe, cyclical mood disorder in which normal hormonal fluctuations during the luteal phase (the 7 to 14 days before menstruation) trigger profound depression, anxiety, irritability and physical symptoms, all of which resolve within a few days of menstrual onset.

PMDD is not "PMS plus." It is now recognized by the DSM-⁠5 as a distinct mental health diagnosis. Research from the NIH and others has shown that women with PMDD do not have abnormal hormone levels; they have an abnormal neurosensitivity to normal estrogen and progesterone fluctuations, especially to the progesterone metabolite allopregnanolone3 and its modulation of GABA-A receptors. Suicidal thoughts and attempts are more common in PMDD2, which makes rapid recognition critical.

Some people notice their symptoms cluster in one of the patterns below. These are patterns, not diagnostic categories: DSM-⁠5 defines PMDD by its symptom criteria, at least five symptoms in the final week before most periods, at least one of them a mood symptom, confirmed by daily ratings over two cycles11.

Premenstrual dysphoric disorder, a woman with low mood, anxiety, irritability, tiredness, bloating and breast tenderness

Classic / Affective PMDD

A pattern dominated by sudden depression, hopelessness, tearfulness and anhedonia in the luteal phase. Women describe feeling "like a different person" until the period starts. Strong response to SSRIs4.

  • โ†’Hallmarks: Profound depression, tearfulness, hopelessness, dread, suicidal ideation in luteal phase
  • โ†’Cycle pattern: Symptoms begin day 14 to 21, resolve within 2 days of period onset

Anger / Irritability-Dominant PMDD

Rage, snapping, interpersonal conflict and impulsive behavior are the dominant features rather than depression. Often described as "Jekyll and Hyde" by partners and family. Often misdiagnosed as borderline or bipolar disorder.

  • โ†’Hallmarks: Explosive anger, rage outbursts, snapping at family, impulsive decisions
  • โ†’Watch-out: Easily misdiagnosed as borderline personality disorder or bipolar II

Anxious / Insomnia-Dominant PMDD

Severe anxiety, panic attacks, racing thoughts and insomnia dominate the luteal phase. Sleep disruption itself worsens every other symptom.

  • โ†’Hallmarks: Panic, racing thoughts, dread, insomnia, hypervigilance in luteal phase
  • โ†’Cycle pattern: Anxiety peaks late luteal, often with insomnia 3 to 7 days before period

PME (Premenstrual Exacerbation of an Existing Disorder)

Technically not PMDD by DSM-⁠5 criteria, but operationally important. Existing depression, anxiety, bipolar, ADHD or migraine symptoms intensify markedly in the luteal phase. Treating the cyclical component reduces overall disease burden.

  • โ†’Hallmarks: Symptoms present all month but markedly worse in the luteal phase
  • โ†’Primary lever: Treat the underlying condition + add luteal-phase cyclical support
  • โ†’Watch-out: Often missed: women think "it's just my depression getting worse"
By the Numbers

PMDD by the Numbers

1.8% to 5.8%
of menstruating women in the US meet PMDD criteria in a given year, the range DSM-⁠5 reports11
5.1
healthcare providers seen on average while seeking a PMDD diagnosis, in a survey of 267 people in Australia; 56% reported a misdiagnosis18
34%
reported a lifetime suicide attempt, and 72% active suicidal thoughts, in a global survey of 599 people with PMDD confirmed by daily ratings; if that is you, the crisis line is 988 in the US19
70%
reported at least one other lifetime psychiatric diagnosis in the same survey19
Final week
before the period is when DSM-⁠5 requires symptoms to be present, improving within a few days of it starting and minimal in the week after11
34 trials
in a 2024 Cochrane review found that SSRIs probably reduce premenstrual symptoms, more so taken all month than only in the second half of the cycle12
Signs & Symptoms

Symptoms of PMDD

PMDD is defined by the timing as much as by the symptoms. Identical-looking depression, anxiety or irritability in the follicular phase (after the period) is NOT PMDD. The cyclical pattern, severe in the luteal phase, gone by day 3 of menses, is what makes the diagnosis.

SymptomWhat happens
Emotional & Cognitive Symptoms
Severe Depression & HopelessnessSudden onset of profound sadness, hopelessness, worthlessness and tearfulness 7 to 14 days before menstruation. Resolves within days of menstrual onset. Suicidal ideation in this window is a recognized PMDD emergency.
Rage & IrritabilityDisproportionate anger, snapping at family or partner, road rage and interpersonal conflict that one would not consider in character. It reflects a response to normal hormone shifts, not personality.
Severe Anxiety & Panic AttacksRacing thoughts, sense of impending doom, panic attacks and hypervigilance that may not be present in the follicular phase at all.
Cognitive Symptoms (Brain Fog, Memory)Significant difficulty with concentration, decision-making and short-term memory in the luteal phase. Reverts to baseline after menstruation begins.
Withdrawal & Loss of Interest (Anhedonia)Activities, people and pleasures that normally bring joy become flat or actively unwanted. Withdrawal from family and friends is common in the late luteal phase.
Suicidal Ideation & Self-Harm UrgesMany women with PMDD experience suicidal thoughts in the luteal phase, and the lifetime suicide attempt rate is substantially higher than in the general population. This is a recognized medical emergency, not a personality flaw or attention-seeking. Safety planning is essential.
Physical, Behavioral & Quality-of-Life Symptoms
Insomnia & Sleep DisturbanceInability to fall asleep despite exhaustion, frequent night waking, vivid distressing dreams and waking 3 to 5 AM with racing thoughts are typical luteal phase sleep patterns. Conversely, hypersomnia and inability to wake also occur.
Carbohydrate Cravings & Binge EatingIntense urges for refined carbs, chocolate and sweet foods in the luteal phase, often progressing to binge episodes.
Headaches & MigrainesHormone-triggered migraines and tension headaches are common, especially in the days before the period when estrogen drops sharply.
Bloating, Breast Tenderness & Weight FluctuationWater retention, severe breast tenderness and abdominal bloating are common. Resolve within 2 to 3 days of menstruation onset.
Severe Fatigue & Low EnergyCrushing tiredness disproportionate to the day's demands, often paired with insomnia (paradoxically).
โš ๏ธ Suicide safety: If you have thoughts of self-harm during your luteal phase, do not wait. Call or text 988 (US Suicide & Crisis Lifeline) or your local crisis line. Tell your provider this is PMDD-pattern (cyclical) and ask to be seen promptly. If you are in immediate danger, call 911 right away8.
Causes

Causes of PMDD

Hormone levels are normal in PMDD3; what differs is how the brain responds to the normal rise and fall of estrogen and progesterone20. Other factors add to the risk, and none of them is a reason to delay treatment.

CauseHow It Contributes to PMDDWhat Helps
Sensitivity to normal hormone changesWhen ovarian hormones were switched off, symptoms disappeared in women with PMDD and returned when estradiol or progesterone was added back, while healthy women stayed well on the same hormones20. The leading explanation is an altered response to allopregnanolone, a progesterone metabolite that acts on GABA-A receptors11Treatment that changes the response: an SSRI and cognitive behavioral therapy (CBT) are first-line options, and ovulation suppression is used under specialist care when they do not work11
SerotoninSerotonin levels change through the cycle, and some women may be more sensitive to those changes21An SSRI, which probably reduces premenstrual symptoms and works better taken all month than only in the luteal phase12
GenesCells from women with PMDD respond differently to ovarian hormones through a gene-silencing complex, and a 2026 genome study of 72,297 women found a strong genetic overlap between premenstrual symptoms and major depression22No gene test guides care. A family history of PMDD or depression is worth telling your clinician, and treatment is the same
Childhood traumaIn 391 people in a prospective cohort, childhood trauma correlated with premenstrual symptom burden, most strongly among those with premenstrual disorders23Trauma-focused therapy alongside PMDD treatment; CBT has the most evidence of the talking therapies11
Another condition that worsens before periodsDepression, panic disorder or another condition that is present all month but worse before a period is not PMDD, though the two can co-occur; daily ratings over at least two cycles tell them apart11Treating the underlying condition, after the psychiatric evaluation in the diagnosis section
Smoking, alcohol and poor sleepThese are among the habits NHS guidance advises changing for premenstrual symptoms24Not smoking, not drinking too much alcohol, plenty of sleep, regular exercise and smaller meals every 2 to 3 hours if that helps24
Diagnosis

How PMDD Is Diagnosed

PMDD is a clinical diagnosis based on the DSM-⁠5 criteria and the requirement of two consecutive months of prospective daily symptom tracking1. There is no blood test, but lab work is used to rule out look-alikes (thyroid, anemia, low ferritin, vitamin D deficiency).

TestWhat it shows
At-Home Screening
The most important diagnostic step for PMDD happens at home, daily tracking. Without it, the cyclical pattern cannot be confirmed and women are misdiagnosed with bipolar, borderline or chronic depression.
DRSP (Daily Record of Severity of Problems)The gold-standard tracking tool, available free from IAPMD. Score 24 symptoms on a 1 to 6 scale every evening for 2 full cycles. PMDD diagnosis requires at least one core symptom at severity 4+ in the luteal phase that drops to 1 to 2 in the follicular phase. The pattern is more important than the absolute scores.
PMDD Symptom Checklist (DSM-⁠5)Score for each in the luteal week: marked depression, marked anxiety/​tension, marked affective lability, persistent anger, decreased interest, difficulty concentrating, lethargy/​fatigue, appetite/​cravings, sleep disturbance, sense of being overwhelmed, physical symptoms. 5+ symptoms (with 1+ from the first four) confirmed over 2 cycles meets DSM-⁠5 PMDD criteria.
Lab & Clinical Tests
Thyroid & Pituitary PanelTSH, free T4, free T3, TPO antibodies6, reverse T3. Hypothyroidism and Hashimoto's produce low mood and fatigue that can be mistaken for PMDD. Treat thyroid first if positive before concluding PMDD.
Nutrient & Inflammation Status25-⁠OH-D where deficiency is suspected, ferritin (often low if heavy periods, contributes to mood and fatigue), B12 + MMA, RBC magnesium, folate, homocysteine.
Reproductive Hormone PanelEstradiol, progesterone (day 21 of cycle for confirmation of ovulation), SHBG, DHEA-S, testosterone, prolactin. Hormone levels are usually normal in PMDD; the disorder is in the brain's response, not the levels. Useful primarily to rule out PCOS, perimenopause and prolactinoma.
Psychiatric Differential EvaluationDetailed history to rule out major depressive disorder (continuous), bipolar I/II, generalized anxiety, borderline personality disorder and complex PTSD. PME (premenstrual exacerbation) is the most common misdiagnosis; the underlying condition needs treatment AND luteal-phase support.
Treatment Comparison

Conventional and Holistic Treatment for PMDD

๐ŸŒฟ HOLISTIC
๐Ÿ’Š CONVENTIONAL
๐ŸŒฟ

Holistic / Functional Approach

Support sleep, regular meals and the supplements with some evidence, alongside medical treatment

Primary Treatment
Cycle-aware nutrition + magnesium/B6/calcium/​omega-⁠3 stack + vitex + sleep restoration + GABA support
Duration
2 to 3 cycles for noticeable change; 6 to 9 months for full stabilization
Effect on Underlying Disorder
Calcium has the best supplement evidence; the rest is mixed and does not address the underlying sensitivity
Fertility & Cycle
Cycle remains intact; chasteberry should be stopped if pregnancy is possible, as it may be unsafe in pregnancy9

Full Holistic Approach Includes

  • Stable blood sugar throughout the cycle, protein-anchored meals, no skipping meals (especially in luteal)
  • Magnesium glycinate 300 to 400 mg + B6 (P5P) 50 to 100 mg (no more than the adult upper limit of 100 mg; long-term high doses can damage nerves)10 + calcium 1,000 to 1,200 mg in divided doses + omega-⁠3 2 g daily. The top of this range is above the 350 mg/day upper intake level for supplemental magnesium; above that, diarrhea is common. With kidney disease, take it only on your clinician's advice.
  • Vitex (chasteberry) 400 to 1,000 mg daily, taken throughout the cycle (8 to 12 weeks for effect)
  • Vitamin D3, at a dose your clinician sets
  • Sleep optimization, 7 to 9 hours, especially in luteal phase, magnesium and lavender at bedtime
  • Cycle-tracking + luteal-phase preparedness (lighter schedule, no big decisions, partner check-ins)
  • Daily walking, strength training 2 to 3x/week, mood-protective and insulin-sensitizing
  • CBT, a first-line option and the talking therapy with the most evidence in PMDD11
โš ๏ธ Side effects: Loose stools from magnesium (reduce dose), occasional irregular cycles from vitex (resolve in 8 to 12 weeks), mild transient fatigue in the first 2 weeks. Supplements have side effects and interactions too, so tell your prescriber what you take.
Supplement Protocol

Evidence-Based Supplements for PMDD

Supplements support treatment rather than replace it. Calcium has the best evidence5, and the rows below report what the trials found.

Supplement What it is for Typical range Timing Notes & cautions
Magnesium GlycinateWidely used in PMDD, but the trial evidence is mixed and generally low quality5300 to 400 mg elemental per dayEvening, 30 to 60 min before bedIn pregnancy, check the dose with your midwife or doctor. Can split AM/PM in luteal week. The top of this range is above the 350 mg/day upper intake level for supplemental magnesium; above that, diarrhea is common. With kidney disease, take it only on your clinician's advice.
Vitamin B6 (P5P)A 1999 review of nine trials in 940 women found B6 more than doubled the odds of improvement over placebo, but most trials were of low quality13; the evidence is weaker than for calcium550 to 100 mg P5P per dayMorning with foodUse P5P (pyridoxal-⁠5-⁠phosphate), not high-dose pyridoxine. Stay within the adult upper limit of 100 mg a day: long-term high doses can cause nerve damage that can be permanent10. In pregnancy, check with your midwife or doctor.
Calcium Carbonate or CitrateIn a trial of 466 women with moderate to severe premenstrual symptoms, 1,200 mg a day cut symptom scores by 48% by the third cycle, against 30% on placebo14.1,000 to 1,200 mg per day, in divided dosesSplit between mealsCitrate is gentler on the stomach. Take separately from iron and zinc supplements. Keep food and supplements together under the 2,500 mg daily upper limit15.
Vitex (Chasteberry)A 2017 meta-analysis of 14 trials found a large effect, but most trials were at high risk of bias; in the three best-described trials, symptoms remitted 2.57 times as often as on placebo9. Overall the evidence is mixed and generally low quality5400 to 1,000 mg per day (standardized extract)Morning, daily throughout cycleTakes 8 to 12 weeks for full effect. Avoid with hormonal contraception, in pregnancy and breastfeeding, and with breast, uterine or ovarian cancer9.
Omega-⁠3 EPA/DHAEPA-dominant omega-⁠3 has some evidence in depression generally; evidence specific to PMDD is limited.2 g combined EPA+DHA per day (EPA-dominant)With mealsChoose a third-party-tested product. In heart trials, fish oil supplements raised the risk of atrial fibrillation, an irregular heartbeat, more so above 1 g a day26, so check this dose with your clinician first.
Vitamin D3 (with K2)Corrects a deficiency. It has not been shown to treat PMDD.D3: set the dose with your clinician; most adults need no blood test first; K2 (MK-⁠7): 100 to 200 mcg per dayWith a fat-containing mealIf you take warfarin, clear any vitamin K supplement with the clinician managing your anticoagulation before starting or stopping it: vitamin K antagonizes warfarin, and changing your intake destabilizes the INR. Consistency matters more than avoidance. This does not apply in the same way to direct oral anticoagulants such as apixaban or rivaroxaban, but tell your prescriber about any supplement you take.
Ashwagandha (standardized root extract)An adaptogen studied for stress; small trials report less stress and anxiety.300 to 600 mg standardized extract per dayEvening preferredAvoid in pregnancy and breastfeeding, before surgery, and with autoimmune or thyroid disorders; rare cases of liver injury have been reported16.
Saffron Extract (Crocus sativus)Small trials suggest benefit in mild to moderate depression and PMS27; evidence in PMDD itself is limited. Thought to act on serotonin and dopamine.30 mg standardized extract twice dailyWith mealsLook for a standardized extract of the kind used in clinical trials. The PMS trial used 15 mg twice a day (30 mg a day)27, half this dose, so agree on the dose with your clinician. If you take an SSRI or other antidepressant, check with your prescriber before adding saffron. Safety at supplement doses in pregnancy is not established: check with your midwife or doctor.
Iron (if Ferritin Low)Heavy periods, if you have them, deplete ferritin. Low ferritin worsens fatigue, mood and restless legs.25 to 65 mg elemental per day (if ferritin < 50 ng/mL)Empty stomach with vitamin CUse bisglycinate or ferrous sulfate. Recheck after 3 months. The top of this range sits above the 45 mg/day tolerable upper intake level for adults. That is appropriate only when correcting a confirmed deficiency under clinical supervision, not as general supplementation. Test ferritin first, and retest rather than staying on it indefinitely.
Lavender Oil (Oral, Standardized)Standardized oral lavender extract with RCT evidence for anxiety, sleep and PMS. Some trials show benefit for anxiety symptoms, though comparative data against prescription therapy is limited.80 mg per day, oral capsuleEvening or daytime as neededChoose the standardized oral preparation used in the trials. Different from aromatic lavender oil. Little is known about its safety in pregnancy or breastfeeding: check with your midwife or doctor17.
What to Expect

What to Expect Over Time

PMDD responds to treatment; the first steps are confirming the pattern and starting a first-line option.

Treatment and supportive care, together
First Weeks

Thoughts of suicide or self-harm come first: see When to Seek Care. Start daily symptom ratings, since PMDD is confirmed over two cycles1, and have blood tests for look-alikes such as thyroid disease and iron deficiency6.

Months 1 to 3

The first-line options are an SSRI, taken all month or only in the second half of the cycle, and CBT; UK guidance also lists exercise, combined pills and vitamin B6 11. SSRIs probably reduce symptoms, more so taken continuously; nausea, low energy and sleepiness are the most common side effects12.

Months 3 to 12

If symptoms persist, combined pills are an option, and ovulation suppression, with surgery as a last resort, has worked where other treatment has not11. Calcium has the best supplement evidence5. Keep rating symptoms to judge what works.

Long Term

If you plan a pregnancy or might be pregnant, stop chasteberry, which may be unsafe in pregnancy, and tell your clinician9. Childhood trauma is linked with heavier premenstrual symptoms, and trauma-focused therapy can sit alongside PMDD treatment23.

When to Seek Care

If you have thoughts of suicide or self-harm, call or text 988 in the US now, and call 911 if you are in immediate danger8. PMDD roughly doubles the odds of suicidal thoughts and attempts25, and the risk clusters in the days before a period2; tell your clinician the pattern is cyclical and ask to be seen promptly.

📬

Get new guides in your inbox. Once a month: new condition guides and research updates, including the trials that did not work. Free, no spam, and you can unsubscribe in one click.

Sign up

Next Steps

PMDD Responds to Treatment

Confirm the pattern with daily symptom ratings, then start a first-line option with your clinician. Nutrition and sleep support that treatment; they do not replace it. If you have thoughts of suicide or self-harm, call or text 988 in the US now.

Explore Polycystic Ovary Syndrome (PCOS) โ†’ Explore Depression โ†’

References & Evidence Notes

Each numbered entry below is either a source you can follow or a note setting out what the evidence does and does not support. Both are numbered together so the markers in the text line up.

Last reviewed October 20, 2026. Supplement entries are cross-checked against the NIH National Center for Complementary and Integrative Health and the Linus Pauling Institute Micronutrient Information Center.7 PMDD is a recognized diagnosis in DSM-⁠5 and ICD-⁠11, not a severe version of PMS and not a personality problem. The most important thing on this page is a safety fact: PMDD carries a substantially raised risk of suicidal thinking and attempts, concentrated in the luteal phase. If you are having thoughts of harming yourself, contact emergency services or a crisis line now; in the US that is 988. Treatments that work exist. SSRIs are first-line and, unusually, often work within a day or two and can be taken only in the luteal phase rather than continuously. Nutrition and sleep support that treatment; they do not replace it, and waiting to try supplements first is a decision with real risk attached.

  1. On diagnosis: PMDD requires symptoms confined to the luteal phase, remitting within a few days of menstruation onset, causing significant impairment, and confirmed by prospective daily rating over at least two cycles rather than by recall. Retrospective diagnosis is unreliable, and prospective charting also separates PMDD from premenstrual exacerbation of an underlying mood disorder, which is treated differently. ↩
  2. On risk: studies consistently report elevated rates of suicidal ideation and attempts in PMDD, with lifetime attempt figures commonly cited around 30%. Risk clusters in the late luteal phase. This is the reason speed of treatment matters and the reason a supplement-first approach is not neutral here. ↩
  3. On the biology, because it changes how the condition is understood: PMDD does not involve abnormal hormone levels. It reflects an atypical central nervous system response to normal fluctuations in progesterone and its neurosteroid metabolite allopregnanolone, which acts at GABA-A receptors. This is why hormone testing is normal and why suppressing ovulation or modulating the response works while "balancing hormones" does not. ↩
  4. On SSRIs: selective serotonin reuptake inhibitors are first-line, with response rates commonly reported around 60 to 70%, and they act far faster in PMDD than in major depression, often within 24 to 48 hours. This allows luteal-phase-only or symptom-onset dosing, which many women prefer. Other options include combined oral contraceptives containing drospirenone, and GnRH analogs with add-back for severe refractory cases. ↩
  5. On calcium, which has the best supplement evidence here: randomized trials of calcium supplementation, commonly 1,000 to 1,200 mg daily, report reductions in premenstrual symptoms. Evidence for vitamin B6 is weaker and doses above 100 mg daily carry a risk of peripheral neuropathy, which is dose and duration dependent and can be irreversible. Magnesium and chasteberry have mixed and generally low-quality evidence. ↩
  6. On what else it might be: thyroid disease, iron deficiency, perimenopause, bipolar disorder and premenstrual exacerbation of depression or anxiety all overlap with PMDD, and several are treated quite differently. Bipolar disorder matters particularly, because an SSRI without a mood stabilizer can destabilize it. Prospective charting plus basic blood tests sorts most of this out. ↩
  7. National Center for Complementary and Integrative Health (NIH), nccih.nih.gov, and the Linus Pauling Institute Micronutrient Information Center, lpi.oregonstate.edu/mic. ↩
  8. On crisis help: NIMH advises anyone struggling or having thoughts of suicide to call or text the 988 Suicide and Crisis Lifeline at 988, and to call 911 in life-threatening situations, NIMH, suicide prevention. ↩
  9. On chasteberry: a 2017 meta-analysis of 14 trials in premenstrual syndrome found a large pooled effect, but most trials were at high risk of bias, results varied widely and publication bias was likely, so no definitive conclusion was possible, PubMed 28237870; a 2019 analysis of the three best-described placebo-controlled trials (520 women) found women on chasteberry 2.57 times as likely to have their symptoms remit, PubMed 31780016. The NIH complementary health center notes it may be unsafe during pregnancy or breastfeeding and for women with hormone-sensitive conditions such as breast, uterine or ovarian cancer, NCCIH, chasteberry. ↩
  10. On vitamin B6 limits: the US tolerable upper intake level for adults is 100 mg a day, and the European limit is 12 mg a day. Long-term high doses can cause a sensory neuropathy with pain and numbness in the hands and feet that can be irreversible; it usually occurs above 1,000 mg a day, but cases have been reported below 500 mg a day taken over months to years, Linus Pauling Institute, vitamin B6. ↩
  11. On treatment evidence: a 2022 scoping review of two decades of research found the highest-quality evidence for SSRIs and combined oral contraceptives, with ovulation suppression and surgery effective in cases that do not respond; among talking therapies the most evidence favors CBT, and UK guidance lists SSRIs, CBT, exercise, combined pills and vitamin B6 among first-line options. It describes allopregnanolone, a progesterone metabolite acting at GABA-A receptors, as the leading explanation, with altered sensitivity to it found in women with PMDD. It reports the DSM-⁠5 12-⁠month prevalence of 1.8% to 5.8% among menstruating women in the US, and sets out the DSM-⁠5 criteria: in most cycles at least five symptoms in the final week before the period, at least one of them a mood symptom, improving within a few days of the period starting and minimal in the week after, confirmed by prospective daily ratings over at least two cycles and not merely a worsening of another disorder, PubMed 36575726. ↩
  12. On SSRIs: a 2024 Cochrane review of 34 trials found that SSRIs probably reduce premenstrual symptoms in PMS and PMDD, more so when taken continuously than only in the luteal phase; nausea, low energy and sleepiness were the most common side effects, and sexual problems were also more frequent. Most of the trials were funded by drug makers, PubMed 39140320. ↩
  13. On vitamin B6: a 1999 systematic review of nine trials in 940 women found that B6 more than doubled the odds of improvement in premenstrual symptoms over placebo (odds ratio 2.32) and helped premenstrual depression, but most trials were of low quality; the authors concluded that doses up to 100 mg a day are likely to help, PubMed 10334745. ↩
  14. On calcium: in a randomized trial of 497 women with moderate to severe premenstrual symptoms (466 analyzed), 1,200 mg a day of calcium as calcium carbonate cut total symptom scores by 48% from baseline by the third cycle, against 30% on placebo. The trial enrolled women with premenstrual syndrome rather than confirmed PMDD, PubMed 9731851. ↩
  15. On the calcium limit: the tolerable upper intake level for calcium, counting food and supplements together, is 2,500 mg a day for adults aged 19 to 50 and 2,000 mg a day from 51, Linus Pauling Institute, calcium. ↩
  16. On ashwagandha safety: the NIH complementary health center notes rare cases linking ashwagandha supplements to liver injury, advises avoiding it during pregnancy and breastfeeding, says it is not recommended before surgery or for people with autoimmune or thyroid disorders, and lists possible interactions with medicines for diabetes, blood pressure, seizures and thyroid disease, sedatives and immunosuppressants, NCCIH, ashwagandha. ↩
  17. On oral lavender: the NIH complementary health center notes that an oral lavender oil product might help anxiety, but the studies were small and lacked independent funding, and that little is known about its safety in pregnancy or breastfeeding, NCCIH, lavender. ↩
  18. On getting diagnosed: in a 2026 survey of 267 people in Australia who had sought care for PMDD, respondents had seen an average of 5.1 healthcare providers while seeking a diagnosis, 56% reported a misdiagnosis, and fewer than one in five had been diagnosed with the methods the DSM recommends, PubMed 41523196. ↩
  19. On self-harm and other diagnoses: in a global online survey, 599 people whose PMDD had been diagnosed from two months of daily ratings reported lifetime active suicidal thoughts (72%), suicide attempts (34%) and non-suicidal self-injury (51%), and 70% reported at least one other lifetime psychiatric diagnosis. Participants were recruited through PMDD support groups and social media, so the figures may run higher than among all people with PMDD, PubMed 35303811. ↩
  20. On the hormone response: when ovarian hormones were suppressed in 34 women with PMDD and 76 healthy women, cyclical symptoms disappeared in PMDD. Anxiety, sadness, irritability and mood swings returned when estradiol or progesterone was added back, which did not happen in the healthy women; irritability and mood swings were tied more closely to progesterone, PubMed 41030005. ↩
  21. On PMDD basics: the US Office on Women's Health notes that serotonin may play a role in PMDD because its levels change through the cycle and some women may be more sensitive to those changes, lists SSRIs, a combined pill, pain relievers, stress management and healthy changes among the treatments, and advises calling 911 right away for thoughts of hurting yourself or others, Office on Women's Health, PMDD. ↩
  22. On genes: cell lines from women with PMDD showed a difference in a hormone-regulated gene-silencing complex, both untreated and in response to estradiol and progesterone, PubMed 28044059. Twin studies suggest premenstrual symptoms are substantially heritable, and a 2026 genome-wide study of 72,297 women found one associated locus and the strongest genetic correlation with major depression, PubMed 42633314. ↩
  23. On childhood trauma: in 391 people from a prospective cohort, childhood trauma correlated weakly with premenstrual symptoms overall and moderately within the group with premenstrual disorders; the authors call for research to improve trauma-focused treatment, PubMed 39444627. ↩
  24. On self-help: NHS guidance for premenstrual symptoms advises regular exercise, a healthy balanced diet, perhaps as smaller meals every 2 to 3 hours, plenty of sleep, not smoking, not drinking too much alcohol and keeping a symptom diary for at least 2 cycles, and advises calling emergency services or going to an emergency department for PMDD with suicidal feelings, NHS, PMS. ↩
  25. On suicide risk: a 2021 meta-analysis of six studies with 8,532 participants found PMDD associated with about twice the odds of suicidal thoughts, plans and attempts, PubMed 34488087. ↩
  26. Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of long-term marine omega-⁠3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(25):1981-⁠1990. PubMed 34612056. Seven trials with 81,210 people followed for about 5 years: omega-⁠3 supplements were linked to a higher risk of atrial fibrillation (hazard ratio 1.25), more so in trials of more than 1 g a day (1.49), and the risk rose with each additional gram. ↩
  27. Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, Akhondzadeh S. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG. 2008;115(4):515-⁠519. PubMed 18271889. In women aged 20 to 45 with PMS, saffron 15 mg twice a day for two menstrual cycles relieved premenstrual symptoms and depression scores more than placebo. ↩